StemCells, Inc. to Participate at 2013 Regen Med Investor Day in New York

StemCells, Inc. to Participate at 2013 Regen Med Investor Day in New York

NEWARK, Calif., April 15, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM) announced today that President and CEO Martin McGlynn will
present an update on the Company's programs and operations at the 2013 Regen
Med Investor Day to be held on Wednesday, April 17, 2013, at the Harmonie
Club, 4 East 60^th Street, New York, NY. Mr. McGlynn is scheduled to make his
presentation at 4:00 pm EDT. In addition, Stephen Huhn, MD, FACS, FAAP, Vice
President and Head of the CNS Program at StemCells, Inc., will participate in
an expert panel discussion on "Therapeutics for a Broad Range of CNS
Diseases," which is scheduled to begin at 11:05 am EDT. All the day's events,
including Mr. McGlynn's presentation and Dr. Huhn's panel discussion, will be
webcast live and available at

The 2013 Regen Med Investor Day, which is organized by the Alliance for
Regenerative Medicine (ARM) and co-hosted by leading financial firms Burrill &
Company, Maxim Group and Piper Jaffray, is intended to provide institutional,
strategic and venture investors unique insight into the investment thesis for
regenerative medicine-based therapeutics and tools.The 2013 Regen Med
Investor Day will begin with keynote talks by Jeff Jonas, President of Shire
Regenerative Medicine and Kieran Murphy, President and CEO, GE Healthcare Life
Sciences. These will be followed by focused discussions among key opinion
leaders, top investment analysts and senior company executives on three of the
industry's more prominent target indications, including disorders of the
central nervous system (CNS). Company presentations, showcasing 16 leading,
publicly traded small- and mid-cap companies in the field, will be in the

Attendance at this event is for credentialed investors and members of the
media only. If you are interested in attending, please contact Laura Parsons
at More information is available at

A replay of the webcast will be available on ARM's website shortly after the

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC®
cells (purified human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system disorders. In
a PhaseI clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company has shown preliminary evidence
of progressive and durable donor-derived myelination in all four patients
transplanted with HuCNS-SC cells.The Company is conducting a Phase I/II
clinical trial in chronic spinal cord injury in Switzerland and recently
reported positive data for the first patient cohort.The Company is also
conducting a Phase I/II clinical trial in dry age-related macular degeneration
(AMD), and is pursuing preclinical studies in Alzheimer's disease. StemCells
also markets stem cell research products, including media and reagents, under
the SC Proven® brand.Further information about StemCells is available at

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein.These
statements include, but are not limited to, statements regarding the clinical
development of the Company's HuCNS-SC cells; the Company's ability to
commercialize drug discovery and drug development tools; and the future
business operations of the Company. These forward-looking statements speak
only as of the date of this news release. The Company does not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. Such statements reflect
management's current views and are based on certain assumptions that may or
may not ultimately prove valid. The Company's actual results may vary
materially from those contemplated in such forward-looking statements due to
risks and uncertainties to which the Company is subject, including those
described under the heading "Risk Factors" in the Company's Annual Report on
Form 10-K for the year ended December 31, 2012 and in its subsequent reports
on Forms 10-Q and 8-K.

CONTACT: Rodney Young
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
         Ian Stone
         Russo Partners
         (619) 308-6541

company logo
Press spacebar to pause and continue. Press esc to stop.